We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Anesthesiological Strategies in Elective Craniotomy (Neuromorfeo)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00741351
Recruitment Status : Completed
First Posted : August 26, 2008
Last Update Posted : September 8, 2011
Information provided by (Responsible Party):

Study Description
Brief Summary:
This protocol, NeuroMorfeo, aims to assess equivalence between volatile and intravenous anesthetics for neurosurgical procedures.

Condition or disease Intervention/treatment Phase
Anesthesia Craniotomy Neurosurgery Drug: Sevoflurane + Fentanyl Drug: Sevoflurane + Remifentanyl Drug: Propofol + Remifentanyl Phase 3

Detailed Description:

NeuroMorfeo is a multicenter, randomized, open label, controlled trial, based on an equivalence design. Patients aged between 18 and 75 years, scheduled for a elective craniotomy for supratentorial lesion without signs of intracranial hypertension, in good physical state evaluated with the ASA (I-III) and Glasgow Coma Scale (GCS) equal to 15, will be randomly assigned to one of three anesthesiological strategies (two VA arms, sevoflurane + fentanyl or sevoflurane + remifentanil, and one IA, propofol + remifentanil). The equivalence between intravenous and volatile-based neuroanesthesia will be evaluated by comparing the intervals required to reach, after anesthesia discontinuation, a modified Aldrete score ≥ 9 (primary end-point). Two statistical comparisons have been planned: 1) sevoflurane + fentanyl vs. propofol + remifentanil; 2) sevoflurane + remifentanil vs. propofol + remifentanil.

Secondary end-points include: an assessment of neurovegetative stress based on (a) measurement urinary catecholamines and plasma and urinary cortisol and (b) estimate of sympathetic/parasympathetic balance by power spectrum analyses of electrocardiographic tracings recorded during anesthesia; intraoperative adverse events (i.e. hypotension, hypertension, requirement of osmotic agents or/and hyperventilation for controlling brain swelling); evaluation of surgical field; postoperative adverse events (as seizures, cough, shivering, agitation, postoperative hematoma and postoperative pain); patient's satisfaction and an analysis of costs.

411 patients will be recruited in 14 different Italian centers during an 18-month period.

The recruitment started December 20th, 2007 and up to 11th March 2009.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 411 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Anesthesiological Strategies in Elective Craniotomy: Randomized, Equivalence, Open Trial
Study Start Date : December 2007
Primary Completion Date : March 2009
Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anesthesia
Drug Information available for: Sevoflurane
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: IF
Sevoflurane (Inhalation)+Fentanyl
Drug: Sevoflurane + Fentanyl
Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary
Experimental: IR
Sevoflurane (Inhalation)+Remifentanyl
Drug: Sevoflurane + Remifentanyl
Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary
Experimental: ER
Propofol (Endovenous)+ Remifentanyl
Drug: Propofol + Remifentanyl
Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary

Outcome Measures

Primary Outcome Measures :
  1. Post-anesthesia awaking time, assessed as the interval (min:sec)required to reach an ALDRETE score ≥ 9 [ Time Frame: From estubation to aldrete score ≥ 9 ]

Secondary Outcome Measures :
  1. Neurovegetative stress [ Time Frame: From induction of anesthesia to 24 hours after surgery ]
  2. Intraoperative and post-operative adverse events assessment [ Time Frame: From induction of anesthesia to 24 hours after surgery ]
  3. Brain relaxation evaluated by a blinded neurosurgeon [ Time Frame: From induction of anesthesia to 24 hours after surgery ]
  4. Patient's satisfaction [ Time Frame: From induction of anesthesia to 24 hours after surgery ]
  5. Costs of the three strategies [ Time Frame: From induction of anesthesia to end of surgery ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Patient scheduled for elective intracranial surgery under general anesthesia for a supratentorial mass lesion in the next 24 hours;
  • Physical state, evaluated with the ASA (American Society of Anesthesiologists ) classification I (normal healthy patient), II (patient with mild systemic disease), or III (patient with severe systemic disease);
  • Age 18-75 years;
  • Normal preoperative level of consciousness, i.e. Glasgow Coma Scale (GCS) = 15;
  • No signs of intracranial hypertension.

Exclusion criteria:

  • Severe cardiovascular pathology, as uncontrolled arterial hypertension, documented reduced coronary reserve.
  • Renal or liver disease precluding the use of either anesthetic technique.
  • Pregnancy .
  • Known allergies to any anesthetic agent.
  • Reduced preoperative level of consciousness, i.e.
  • Glasgow Coma Scale (GCS) < 15.
  • Body weight greater than 120 kg.
  • History of drug abuse or psychiatric conditions.
  • Documented disturbance of the hypothalamic region.Refusal to sign consent form.
  • Participation in other clinical trials.
  • Delayed awakening, because, due to the location or size of the lesion, postoperative sedation and mechanical ventilation are planned.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00741351

Policlinico Consorziale di Bari
Bari, Italy
Ospedale Bellaria Bologna
Bologna, Italy, 40100
IRCCS Fondazione San Raffaele Milano
Milan, Italy, 20100
Istituto di Ricerche Farmacologiche Mario Negri - Dipartimento di Ricerca Cardiovascolare-
Milan, Italy, 20100
Azienda Ospedaliera San Gerardo
Monza, Italy, 20052
Ospedale Maggiore della Carità di Novara
Novara, Italy, 28100
Ospedale di Padova
Padua, Italy, 35128
Azienda Ospedaliera di Parma
Parma, Italy, 43100
Policlinico "A. Gemelli" Roma
Rome, Italy
Policlinico "Umberto I" Roma
Rome, Italy
Azienda Universitaria Senese
Siena, Italy, 53100
Ospedale San Giovanni Bosco Torino
Turin, Italy, 10057
Ospedale San giovanni Battista Torino
Turin, Italy
Ospedale di Circolo e Fondazione Macchi Varese
Varese, Italy, 21100
Azienda Ospedaliera Universitaria di Verona
Verona, Italy, 37121
Sponsors and Collaborators
Azienda Ospedaliera San Gerardo di Monza
Principal Investigator: Giuseppe Citerio, MD Azienda Ospedaliera San Gerardo Monza
Study Chair: Antonio Pesenti, MD Università delgi Studi Milano Bicocca
Study Chair: Maria Grazia Franzosi, PhD Istituto Di Ricerche Farmacologiche Mario Negri
Study Chair: Roberto Latini, MD Istituto Di Ricerche Farmacologiche Mario Negri
More Information


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dott. Giuseppe Citerio, MD, Azienda Ospedaliera San Gerardo di Monza
ClinicalTrials.gov Identifier: NCT00741351     History of Changes
Other Study ID Numbers: EudraCT number 2007-005279-32
First Posted: August 26, 2008    Key Record Dates
Last Update Posted: September 8, 2011
Last Verified: September 2011

Keywords provided by Dott. Giuseppe Citerio, Azienda Ospedaliera San Gerardo di Monza:

Additional relevant MeSH terms:
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anesthetics, Intravenous
Anesthetics, General
Analgesics, Opioid
Sensory System Agents
Peripheral Nervous System Agents
Adjuvants, Anesthesia
Platelet Aggregation Inhibitors
Anesthetics, Inhalation